Company research
Foghorn Therapeutics Inc.
CIK 1822462Updated Nov 10, 2026
FHTX price & chart
Loading TradingView…
NASDAQ:FHTX on TradingView ↗About the company
Foghorn® Therapeutics is discovering and developing a novel class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Through its proprietary, scalable Gene Traffic Control® platform, Foghorn is systematically studying, identifying, and validating potential drug targets within the chromatin regulatory system. The Company is developing multiple product candidates in oncology. Visit our website at www.foghorntx.com for more information on the Company, and follow us on X and LinkedIn.
In the news
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Foghorn Therapeutics Inc. - FHTX ↗
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Foghorn Therapeutics Inc. - FHTX ↗
Next-Generation DNA Repair Therapies Open New Frontiers in Oncology ↗
Seeking Alpha
Russell 2000 estimated to drop 83 stocks in December rebalance - Stephens ↗
Foghorn: Downgrade 'Sell' Eli Lilly Exit FHD-909 And Shift To Preclinical Assets ↗
Foghorn extends losses as TD Cowen cuts on Lilly exit ↗
SEC disclosures
Foghorn Therapeutics Inc. files 8-K: Material Event ↗
Recent filings
10-Q filing
Results of Operations and Financial Condition · Regulation FD Disclosure
Items 2.02, 7.01, 9.01
3 filing
SCHEDULE 13G/A - filed by BIOTECHNOLOGY VALUE FUND L P regarding Foghorn Therapeutics Inc.
Costs Associated with Exit or Disposal Activities · Regulation FD Disclosure
Items 2.05, 7.01, 9.01
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 204,962,000Source | 308,372,000Source | 203,393,000Source | 226,236,000Source | 328,585,000Source | 222,167,000Source | 258,691,000Source | 255,004,000Source | 198,103,000Source | 283,982,000Source | 285,916,000Source | 404,883,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 89,334,000Source | 57,678,000Source | 68,080,000Source | 72,572,000Source | 138,947,000Source | 87,663,000Source | 61,026,000Source | 79,253,000Source | 80,876,000Source | 55,454,000Source | 80,336,000Source | 52,214,000Source |
| Assets, CurrentUSD | 184,117,000Source | 271,234,000Source | 170,046,000Source | 203,842,000Source | 289,621,000Source | 188,064,000Source | 225,416,000Source | 211,520,000Source | 163,235,000Source | 249,601,000Source | 240,181,000Source | 351,399,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 2,589,000Source | 3,837,000Source | 2,464,000Source | 3,927,000Source | 4,444,000Source | 3,183,000Source | 4,829,000Source | 4,859,000Source | 3,091,000Source | 5,854,000Source | 6,124,000Source | 5,601,000Source |
| Operating Lease, Right-of-Use AssetUSD | 10,178,000Source | 24,069,000Source | 29,847,000Source | 10,874,000Source | 25,495,000Source | 30,388,000Source | 21,192,000Source | 28,537,000Source | 30,949,000Source | 22,641,000Source | 29,956,000Source | 34,086,000Source |
| Other Assets, NoncurrentUSD | 5,000Source | 848,000Source | 3,000Source | 6,000Source | 1,001,000Source | 3,000Source | 24,000Source | 1,052,000Source | 4,000Source | 68,000Source | 1,115,000Source | 2,379,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 294,620,000Source | 336,659,000Source | 284,434,000Source | 302,895,000Source | 342,907,000Source | 298,575,000Source | 320,343,000Source | 352,490,000Source | 306,603,000Source | 329,510,000Source | 363,106,000Source | 404,771,000Source |
| Stockholders’ equity: | ||||||||||||
| Preferred Stock, Value, IssuedUSD | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source |
| Common Stock, Value, IssuedUSD | 6,000Source | 6,000Source | 6,000Source | 6,000Source | 6,000Source | 6,000Source | 6,000Source | 4,000Source | 6,000Source | 6,000Source | 4,000Source | 4,000Source |
| Additional Paid in CapitalUSD | 521,115,000Source | 510,028,000Source | 578,620,000Source | 518,333,000Source | 505,569,000Source | 576,061,000Source | 515,346,000Source | 399,587,000Source | 523,937,000Source | 512,515,000Source | 395,196,000Source | 377,232,000Source |
| Retained Earnings (Accumulated Deficit)USD | -610,803,000Source | -538,681,000Source | -659,533,000Source | -594,954,000Source | -519,559,000Source | -652,342,000Source | -577,018,000Source | -496,580,000Source | -632,467,000Source | -558,184,000Source | -471,564,000Source | -373,138,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 24,000Source | 360,000Source | -134,000Source | -44,000Source | -338,000Source | -133,000Source | 14,000Source | -497,000Source | 24,000Source | 135,000Source | -826,000Source | -3,986,000Source |
| Stockholders' Equity Attributable to ParentUSD | -89,658,000Source | -28,287,000Source | -81,041,000Source | -76,659,000Source | -14,322,000Source | -76,408,000Source | -61,652,000Source | -97,486,000Source | -108,500,000Source | -45,528,000Source | -77,190,000Source | 112,000Source |
| Liabilities and EquityUSD | 204,962,000Source | 308,372,000Source | 203,393,000Source | 226,236,000Source | 328,585,000Source | 222,167,000Source | 258,691,000Source | 255,004,000Source | 198,103,000Source | 283,982,000Source | 285,916,000Source | 404,883,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 85,088,000Source | 56,824,000Source | 50,579,000Source | 77,786,000Source | 50,871,000Source | 64,404,000Source | 71,309,000Source | 52,065,000Source | 59,738,000Source | 66,989,000Source | 58,436,000Source | 55,205,000Source |
| Operating Lease, Liability, CurrentUSD | 6,755,000Source | 8,770,000Source | 2,819,000Source | 6,176,000Source | 9,067,000Source | 1,863,000Source | 9,114,000Source | 8,668,000Source | 923,000Source | 9,067,000Source | 8,518,000Source | 5,970,000Source |
| Accounts Payable, CurrentUSD | 3,212,000Source | 3,451,000Source | 3,207,000Source | 3,322,000Source | 4,813,000Source | 3,317,000Source | 4,069,000Source | 5,631,000Source | 4,266,000Source | 3,785,000Source | 6,260,000Source | 5,414,000Source |
| Operating Lease, Liability, NoncurrentUSD | 15,774,000Source | 30,300,000Source | 40,283,000Source | 17,522,000Source | 28,064,000Source | 40,131,000Source | 25,738,000Source | 34,311,000Source | 40,347,000Source | 28,064,000Source | 36,555,000Source | 45,537,000Source |
| Other Liabilities, NoncurrentUSD | 656,000Source | — | 350,000Source | 757,000Source | — | 453,000Source | 856,000Source | — | 556,000Source | — | 0Source | 29,000Source |
| Additional Financial Items | ||||||||||||
| Accrued Liabilities, CurrentUSD | 9,822,000Source | 11,219,000Source | 7,960,000Source | 8,564,000Source | 6,452,000Source | 6,924,000Source | 6,454,000Source | 6,265,000Source | 11,357,000Source | 8,531,000Source | 9,108,000Source | 11,001,000Source |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation, Depletion and AmortizationUSD | — | — | 900,000Source | 700,000Source | 200,000Source | 900,000Source | 238,000Source | 827,000Source | 3,332,000Source | 3,120,000Source | 3,451,000Source | 3,321,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | 2,733,000Source | 3,018,000Source | 2,550,000Source | 2,733,000Source | 2,383,000Source | 2,692,000Source | 10,399,000Source | 11,893,000Source | 16,186,000Source | 14,336,000Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | -990,000Source | 284,000Source | 481,000Source | -2,475,000Source | 846,000Source | 1,614,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -25,266,000Source | -23,968,000Source | -86,099,000Source | -100,406,000Source | -118,106,000Source | 193,612,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | -17,719,000Source | 29,401,000Source | 112,040,000Source | -29,904,000Source | 144,450,000Source | -244,322,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | 0Source | 28,000Source | 50,000Source | 906,000Source | 1,224,000Source | 1,210,000Source |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 49,772,000Source | 139,000Source | 1,023,000Source | 105,428,000Source | 1,778,000Source | 1,763,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 92,584,000Source | 59,386,000Source | 70,080,000Source | 75,822,000Source | 90,913,000Source | 62,734,000Source | 84,126,000Source | 57,162,000Source | 82,044,000Source | 53,922,000Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | — | — | — | — | — | — | — | 3,551,000Source | 0Source |
| Income Taxes Paid, NetUSD | — | — | — | — | — | — | 2,000Source | 4,000Source | 9,000Source | 860,000Source | — | — |
| Additional Financial Items | ||||||||||||
| Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber PropertyUSD | — | — | — | — | — | — | — | — | -31,000Source | 0Source | -3,000Source | -6,000Source |
| Gain (Loss) on Extinguishment of DebtUSD | — | — | — | — | — | — | — | — | — | — | — | 0Source |
| General and Administrative ExpenseUSD | — | — | 6,652,000Source | 6,971,000Source | 6,354,000Source | 6,862,000Source | 6,581,000Source | 7,239,000Source | 27,550,000Source | 28,359,000Source | 32,372,000Source | 30,747,000Source |
| Income Tax Expense (Benefit)USD | — | — | — | 0Source | — | — | — | — | 0Source | 0Source | 4,226,000Source | — |
| Marketable Securities, Unrealized Gain (Loss)USD | — | — | 68,000Source | 698,000Source | — | -58,000Source | — | -121,000Source | -111,000Source | 961,000Source | 3,160,000Source | -3,976,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -15,849,000Source | -19,122,000Source | -7,191,000Source | -17,936,000Source | -19,875,000Source | -18,834,000Source | -74,283,000Source | -86,620,000Source | -98,426,000Source | -108,882,000Source |
| Nonoperating Income (Expense)USD | — | — | 2,652,000Source | 4,730,000Source | 1,614,000Source | 3,161,000Source | 1,698,000Source | 4,079,000Source | 12,106,000Source | 16,063,000Source | 13,706,000Source | 8,255,000Source |
| Operating ExpensesUSD | — | — | 26,654,000Source | 31,660,000Source | 24,877,000Source | 28,654,000Source | 24,840,000Source | 28,865,000Source | 117,298,000Source | 125,285,000Source | 142,061,000Source | 136,365,000Source |
| Other Nonoperating Income (Expense)USD | — | — | — | — | — | — | — | — | — | — | — | 2,580,000Source |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | 49,999,000Source | 0Source | — | 103,401,000Source | — | — |
| Proceeds from Stock Options ExercisedUSD | — | — | — | — | — | — | 89,000Source | 139,000Source | 483,000Source | 2,612,000Source | 1,778,000Source | 1,763,000Source |
| Stock or Unit Option Plan ExpenseUSD | — | — | — | — | — | — | — | — | — | — | — | 14,336,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating Lease, Impairment Loss | — | — | — | — | — | — | — | — | — | — | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | 8,153,000Source | 7,808,000Source | 16,072,000Source | 7,557,000Source | 3,267,000Source | 5,952,000Source | 30,909,000Source | 22,602,000Source | 34,155,000Source | 19,228,000Source |
| Operating Income (Loss)USD | — | — | -18,501,000Source | -23,852,000Source | -8,805,000Source | -21,097,000Source | -21,573,000Source | -22,913,000Source | -86,389,000Source | -102,683,000Source | -107,906,000Source | -117,137,000Source |
| Other Nonoperating Income (Expense)USD | — | — | — | — | — | — | — | — | — | — | — | 2,580,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | — | -19,122,000Source | — | — | — | — | — | -86,620,000Source | -94,200,000Source | — |
| Income Tax Expense (Benefit)USD | — | — | — | 0Source | — | — | — | — | 0Source | 0Source | 4,226,000Source | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | -15,849,000Source | -19,122,000Source | -7,191,000Source | -17,936,000Source | -19,875,000Source | -18,834,000Source | -74,283,000Source | -86,620,000Source | -98,426,000Source | -108,882,000Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.25Source | -0.31Source | -0.1Source | -0.28Source | -0.29Source | -0.3Source | -1.18Source | -1.58Source | -2.34Source | -2.62Source |
| Earnings Per Share, DilutedUSD per share | — | — | -0.25Source | -0.31Source | -0.1Source | -0.28Source | -0.29Source | -0.3Source | -1.18Source | -1.58Source | -2.34Source | -2.62Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 63,029,293Source | 62,602,848Source | 70,629,419Source | 62,978,219Source | 69,540,075Source | 62,848,673Source | 62,980,959Source | 54,899,432Source | 41,974,484Source | 41,591,433Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 63,029,293Source | 62,602,848Source | 70,629,419Source | 62,978,219Source | 69,540,075Source | 62,848,673Source | 62,980,959Source | 54,899,432Source | 41,974,484Source | 41,591,433Source |
| Additional Financial Items | ||||||||||||
| General and Administrative ExpenseUSD | — | — | 6,652,000Source | 6,971,000Source | 6,354,000Source | 6,862,000Source | 6,581,000Source | 7,239,000Source | 27,550,000Source | 28,359,000Source | 32,372,000Source | 30,747,000Source |
| Interest Income, OtherUSD | — | — | 2,032,000Source | 3,495,000Source | 1,609,000Source | 2,309,000Source | 1,742,000Source | 2,692,000Source | 8,745,000Source | 11,900,000Source | 10,875,000Source | 5,675,000Source |
| Nonoperating Income (Expense)USD | — | — | 2,652,000Source | 4,730,000Source | 1,614,000Source | 3,161,000Source | 1,698,000Source | 4,079,000Source | 12,106,000Source | 16,063,000Source | 13,706,000Source | 8,255,000Source |
| Operating ExpensesUSD | — | — | 26,654,000Source | 31,660,000Source | 24,877,000Source | 28,654,000Source | 24,840,000Source | 28,865,000Source | 117,298,000Source | 125,285,000Source | 142,061,000Source | 136,365,000Source |
| Research and Development ExpenseUSD | — | — | 20,002,000Source | 24,689,000Source | 18,523,000Source | 21,792,000Source | 18,259,000Source | 21,626,000Source | 85,466,000Source | 94,528,000Source | 109,689,000Source | 105,618,000Source |
Filing attachments
d31462dex41.htm · 8-K · 2026-01-12
Exhibit 4.1 FOGHORN THERAPEUTICS INC. FORM OF WARRANT TO PURCHASE COMMON STOCK Number of Shares: [ ] (subject to adjustment) Series [1][2] Warrant No. [1][2][-[ ] Original Issue Date: [ ] Foghorn Therapeutics Inc., a Delaware corporation (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [ ] or its permitted…
Read attachment ↗d31462dex42.htm · 8-K · 2026-01-12
Exhibit 4.2 FOGHORN THERAPEUTICS INC. FORM OF PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK Number of Shares: [ ] (subject to adjustment) Warrant No. [ ] Original Issue Date: [ ] Foghorn Therapeutics Inc., a Delaware corporation (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [ ]. or its permitted registered assigns (the “Holder”), is entitled, subje…
Read attachment ↗d31462dex991.htm · 8-K · 2026-01-12
Exhibit 99.1 Foghorn Therapeutics Highlights January Equity Financing, Program Progress and Strategic Objectives for 2026 Recently raised $50 million with BVF Partners, Deerfield Management, founding investor Flagship Pioneering and a leading biotech mutual fund in a transaction that will close January 13 th, 2026 Phase 1 dose-escalation trial of FHD-909 (LY4050784) advancing as planned, targeting SMARCA4 (BRG1)-mutant cancers with a focus on non-small cell lung cancer (NSCLC) Selective CBP …
Read attachment ↗d31462dex992.htm · 8-K · 2026-01-12
Exhibit 99.2 Unique biology Precision therapeutics Broad impact FHTX January 2026 NASDAQ LISTED 2 | Forward Looking Statements This currently presentation available contains to management forward.- looking All statements statements other that than are statements based on of management’s historical facts beliefs contained and assumptions in this presentation and on are information forward-looking “anticipates,” statements “intends,”. In some “plans,” cases, “seeks,” you can “believes,” identify…
Read attachment ↗